What does D4-PHARMA do?

D4-PHARMA is a pharmacy in Etterbeek. Private Limited, started on 10 February 2017, 2 establishments.

What is the address of D4-PHARMA?

The registered office of D4-PHARMA is located at Legerlaan 7, 1040 Etterbeek.

Is D4-PHARMA still active?

Yes. According to the CBE (31 October 2026) D4-PHARMA is active, legal situation “Normale toestand”, started on 10 February 2017.

Is D4-PHARMA registered on Peppol?

Yes, D4-PHARMA is registered on the Peppol network with ID 0208:0670945535.

What is the enterprise number of D4-PHARMA?

The enterprise number of D4-PHARMA is BE0670945535.

When was D4-PHARMA founded?

D4-PHARMA was founded on 10 February 2017.

Who are the directors of D4-PHARMA?

According to the 2025 annual accounts, the directors of D4-PHARMA are: AGANJU HOLDING SRL.

Is D4-PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 10 February 2017; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account; 2 establishments in the CBE.

How much profit did D4-PHARMA make in 2025?

D4-PHARMA posted a profit after taxes of € 15,203 in financial year 2025.

What is the revenue of D4-PHARMA?

As a small company, D4-PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 740,002.

How much does an employee at D4-PHARMA earn?

The average wage cost per full-time employee at D4-PHARMA was € 58,000 in 2025: staff costs of € 608,551 for 10.5 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does D4-PHARMA have?

According to the 2025 annual accounts, D4-PHARMA has 10.5 full-time equivalents (FTE).

D4-PHARMA (Private Limited) - Etterbeek - BE0670945535

Dossier D4-PHARMA, printed on 31 October 2026 from databakkes.be/en/0670945535/d4-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 12.6 to 10.5.

Financials

Financial year 2025

D4-PHARMA from Etterbeek, company number BE0670945535, closed financial year 2025 with a result of € 15,203 after tax. For that financial year D4-PHARMA recorded a gross margin of € 740,002 and equity of € 167,820. Compared with financial year 2024, the result moved from € 85,204 to € 15,203. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Healthy

€ 167,820

▼ 26% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 15,203

▼ 82% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 122,742

▲ 99% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 75,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

10.5

▼ 0.9 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 608,551

▲ 4% vs 2024

€ 58,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 34,306

▲ € 29,356 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 892,286

▲ 195% vs 2024

€ 286,014 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 498,201

▲ 24% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 90,903

▼ 25% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 598,689 Gross margin 2022: € 598,689 First fiscal year in the series	€ 618,767 Gross margin 2023: € 618,767 ▲ 3% vs 2022 (€ 598,689) Favourable step	€ 717,320 Gross margin 2024: € 717,320 ▲ 16% vs 2023 (€ 618,767) Favourable step	€ 740,002 Gross margin 2025: € 740,002 ▲ 3% vs 2024 (€ 717,320) Favourable step	▲ 3%
Profit after taxes	€ -31,596 Profit after taxes 2022: € -31,596 First fiscal year in the series	€ -19,246 Profit after taxes 2023: € -19,246 ▲ € 12,350 vs 2022 (€ -31,596) Favourable step	€ 85,204 Profit after taxes 2024: € 85,204 ▲ € 104,450 vs 2023 (€ -19,246) Favourable step	€ 15,203 Profit after taxes 2025: € 15,203 ▼ 82% vs 2024 (€ 85,204) Unfavourable step	▼ 82%
Equity	€ 236,659 Equity 2022: € 236,659 First fiscal year in the series	€ 217,413 Equity 2023: € 217,413 ▼ 8% vs 2022 (€ 236,659) Unfavourable step	€ 227,617 Equity 2024: € 227,617 ▲ 5% vs 2023 (€ 217,413) Favourable step	€ 167,820 Equity 2025: € 167,820 ▼ 26% vs 2024 (€ 227,617) Unfavourable step	▼ 26%
Total debts	€ 751,876 Total debts 2022: € 751,876 First fiscal year in the series	€ 770,780 Total debts 2023: € 770,780 ▲ 3% vs 2022 (€ 751,876) Unfavourable step	€ 950,311 Total debts 2024: € 950,311 ▲ 23% vs 2023 (€ 770,780) Unfavourable step	€ 1,606,615 Total debts 2025: € 1,606,615 ▲ 69% vs 2024 (€ 950,311) Unfavourable step	▲ 69%
Cash	€ 63,692 Cash 2022: € 63,692 First fiscal year in the series	€ 85,395 Cash 2023: € 85,395 ▲ 34% vs 2022 (€ 63,692) Favourable step	€ 61,608 Cash 2024: € 61,608 ▼ 28% vs 2023 (€ 85,395) Unfavourable step	€ 122,742 Cash 2025: € 122,742 ▲ 99% vs 2024 (€ 61,608) Favourable step	▲ 99%
Retained profit	€ 216,254 Retained profit 2022: € 216,254 First fiscal year in the series	€ 197,008 Retained profit 2023: € 197,008 ▼ 9% vs 2022 (€ 216,254) Unfavourable step	€ 207,212 Retained profit 2024: € 207,212 ▲ 5% vs 2023 (€ 197,008) Favourable step	€ 147,415 Retained profit 2025: € 147,415 ▼ 29% vs 2024 (€ 207,212) Unfavourable step	▼ 29%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 75,000 Dividend 2024: € 75,000 Unchanged (€ 0) Unchanged	€ 75,000 Dividend 2025: € 75,000 Unchanged (€ 75,000) Unchanged
Bank debt	€ 334,683 Bank debt 2022: € 334,683 First fiscal year in the series	€ 324,826 Bank debt 2023: € 324,826 ▼ 3% vs 2022 (€ 334,683) Favourable step	€ 301,964 Bank debt 2024: € 301,964 ▼ 7% vs 2023 (€ 324,826) Favourable step	€ 892,286 Bank debt 2025: € 892,286 ▲ 195% vs 2024 (€ 301,964) Unfavourable step	▲ 195%
Balance sheet total	€ 988,535 Balance sheet total 2022: € 988,535 First fiscal year in the series	€ 988,193 Balance sheet total 2023: € 988,193 Unchanged (€ 988,535) Unchanged	€ 1,177,928 Balance sheet total 2024: € 1,177,928 ▲ 19% vs 2023 (€ 988,193) Unchanged	€ 1,774,435 Balance sheet total 2025: € 1,774,435 ▲ 51% vs 2024 (€ 1,177,928) Unchanged	▲ 51%
Employees (FTE)	12.2 Employees (FTE) 2022: 12.2 First fiscal year in the series	12.6 Employees (FTE) 2023: 12.6 ▲ 0.4 vs 2022 (12.2) Unchanged	11.4 Employees (FTE) 2024: 11.4 ▼ 1.2 vs 2023 (12.6) Unchanged	10.5 Employees (FTE) 2025: 10.5 ▼ 0.9 vs 2024 (11.4) Unchanged	▼ 0.9

Key figures of D4-PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to D4-PHARMA?

What happened at D4-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: profit of € 15,203 (▼ 82% vs 2024). filed late Source: NBB ↗
2021 AGANJU HOLDING SRL became a director. NBB
Feb 10, 2017 New establishment in Etterbeek. KBO
Feb 10, 2017 New establishment in Elsene. KBO
Feb 10, 2017 Start of the company according to the CBE. KBO

In short

From € 31,596 loss in 2022 to € 15,203 profit in 2025.

Paid € 9,429 in corporate taxes since 2022.

Best year ever: 2024, with € 85,204 profit.

On average € 70,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

AGANJU HOLDING 100%

The stake of AGANJU HOLDING comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

D4-PHARMA

Behind D4-PHARMA is AGANJU HOLDING SRL. The shares are held by AGANJU HOLDING (100%).

Directors

According to the 2025 annual accounts

AGANJU HOLDING SRL

Director · represented by HAMIAFO NGATCHI HERVE

Also active at: AGANJU CONCEPT, D5-PHARMA, PHARMACIE DES ARCHIDUCS, CENTRE MEDICAL DEWAND, PHARMACIE DU ROOSENDAEL

since 2021

Shareholders

AGANJU HOLDING

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Legerlaan 7

1040 Etterbeek

2.262.287.745

Maria Malibranstraat 19

1050 Elsene

Active since 10 February 2017

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

AGANJU HOLDING same network

€ 205,924 gross margin · 2025

MEDMISSION

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0670.945.535
VAT number: BE 0670.945.535
Registered office: Legerlaan 7, 1040 Etterbeek
Names & denominations: D4-PHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 10 February 2017
Peppol: Active · Active since 11 Dec 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗